Histone deacetylases (HDACs) are crucial gene regulating enzymes that control the expression of histones-epigenetic targets in research related to developing new therapies for cancer, central nervous system disorders, and heart disease.
1
The deacetylation of histones is a vital repression process in transcriptional gene expression; it also affects apoptosis, cell-cycle arrest, and angiogenesis.
2 Therefore, a number of HDAC inhibitors have been developed; some are already used as antitumor drug candidates and many others are in phase I-III clinical trials.
3 In October 2006, the HDAC inhibitor Vorinostat (SAHA) was the first FDA-approved HDAC-targeting drug for the treatment of cutaneous T cell lymphoma (CTCL).
4 Several benzamide inhibitors, advanced second-generation inhibitors of HDACs, are currently in clinical development and clinical trials for the treatment of various cancers, including follicular lymphoma and acute myeloid leukemia.
5
Accordingly, the use of HDACs as epigenetic biomarkers may be general across many diseases, with HDAC tracers possibly having widespread translational impact because the development of such a new diagnostic technology will allow researchers to directly probe HDACs.
Fluorescence probes are powerful molecular recognition systems with many merits.
6 These attractive imaging tools have been applied in many biological and molecular imaging studies.
7 They typically provide high sensitivity, fully three-dimensional imaging capabilities over large fields of view, and highly quantitative results; in addition, when used as tracers, they minimize biological disturbance during the imaging process, thereby enabling repeated studies. Thus, fluorescence-based HDAC probing systems would be useful and powerful diagnostic tools for imaging these enzymes. The development of fluorescent tracers for HDACs has been difficult because such tracers must have two intrinsic properties -strong fluorescence and strong binding to an HDAC enzyme (much like an inhibitor)-if they are to confer high resolution, high sensitivity, and high specificity of detection to expand the potential impact of imaging. Thus, for this study we chose to modify a benzamide drug, having a hydrophobic planar structure of two aromatic rings, with a fluorescent signaling unit, with the aim of not interfering with its binding affinity toward HDAC enzymes. Attaching a preformed fluorophore to a benzamide drug would inevitably interfere with its binding affinity; therefore, we wished to impart the fluorescence properties to the benzamide derivatives themselves.
In this paper, we report the development of several fluorescent benzamide derivatives as selective HDAC inhibitors. Here, we chose thiophene derivatives to confer fluorescence to the aromatic groups of the benzamides. 8 To ensure that they would not interfere with the binding properties of the benzamides, we synthesized several derivatives substituted at the R 1 and R 2 positions, which are more flexible for modification; we avoided substitutions at the benzamide and free amino positions because they are essential structures for zinc binding in HDAC enzymes, as confirmed computationally (Scheme 1).
9
We fixed the R 2 position with a tertiary amino group to ensure a polarity balance, while modifying the R 1 position with several thiophene derivatives to provide a diverse set of electronic structures (with H, NO 2 , CHO, and CH 3 CO as electron withdrawing groups) to produce spectra variety of fluorescence properties. We used Boc-protected 2-nitro-4-bromophenyl amine as our starting material, which we coupled with pinacol diborane to provide the boronic ester compound (See Scheme S1). Only when 1,4-dioxane was the solvent did we produce the cross-coupling product; DMF and DMSO provided the homocoupled side product, while toluene gave a low conversion. Next, we followed Suzukicoupling to attach thiophene derivative to R1 position. Interestingly, prior to reduction of the electron-withdrawing nitro group, none of these derivatives exhibited fluorescence. In contrast, after reduction to form the electron-donating amino group, each derivative displayed a strong fluorescence signal. Thus, the fluorescence properties presumably involvScheme 1. Designed thienyl-benzamide derivatives.
ed the electron-donating amino groups interacting with the electron-withdrawing thiophene units. When we coupled these thienyl amines with chloromethyl benzoyl chloride, we could not obtain the benzamide products as a major compound because of instability of fluorophore product. Therefore, we reversed our synthetic strategy; first we reacted chloromethylbenzoyl chloride with the boronic ester compound 3 to produce the benzamide scaffold 4 and then we attached the thiophene derivatives to provide the fluorescent benzamides (See Scheme S1). Finally, we attached a dimethylamine unit to the R 2 position and then deprotected the Boc group to produce final compounds TB1-TB5 as free amines. Table 1 lists the absorption, fluorescence, and quantum yields of the benzamide thiophene derivatives TB1-TB5. The range of absorption maxima extended from 317 to 419 nm. Interestingly, TB1 emits a band at a value of λ max of 403 nm, with TB3 at 558 nm, TB4 at 475 and 547 nm, and TB5 at 495 nm, thereby presenting colors ranging from blue to green ( Figure S1 ). Interestingly, the presence of the strongly electron withdrawing NO 2 group in TB2 resulted in no fluorescence emission, whereas is the other tested substituents provided fluorescence.
Next, we checked the quantum yields of these compounds to determine their fluorescence efficiencies, using 2,5-diphenyloxazole as a reference compound. TB1 exhibited the highest quantum yield with a blue signal; TB3, presenting an aldehydic substituent, provided a relatively low quantum yield; TB4 and TB5, which differ only by the position of their attached methylketone units on the thiophene ring, exhibited medium quantum efficiencies and green colors. When we tested the solubility of these benzamide derivatives, we found that only two of them, TB1 and TB4, were soluble in water. Accordingly, we suspect that TB1 and TB4 would be good candidates for use as diagnostic materials for imaging HDAC enzymes. Finally to determine the potency and selectivity as a HDAC inhibitor we examined IC 50 of our thiophene benzamide derivatives using fluorometric assay method.
11 The binding affinity of TB1 showed high binding affinity (IC 50 = 2.9 nM and 5.5 nM) to the HDAC 1 and HDAC 2 ( Figure S2 ).
In summary, we have synthesized a series of novel fluorescent benzamides inhibitors possessing intrinsic fluorescence properties. Most of these benzamide fluorophores exhibit high quantum yields, making them suitable for use in imaging studies, with colors ranging from blue to green; a couple of them were also water-soluble. Notably, TB1 and TB2 display a high quantum yield and TB1 exhibits high binding affinity to HDAC enzymes. We believe that these new fluorescent benzamide inhibitors might be useful diagnostic tools for in vitro studies of HDACs. 
